The Food and Drug Administration recently approved a drug-coated stent for use in angioplasty procedures. The stent is expected to reduce the rate of repeat procedures due to restenosis and delay the need for more invasive surgery, such as coronary bypass surgery. However, the drug-coated stent is three times more than uncoated stents, which would increase the cost of medical procedures. Public demand for the stent is overwhelming, however, due to high costs and the huge demand, the cost of medical care can increase dramatically. Considering a compromise between quality improvement and higher costs for medical treatment, looking at the impact on a range of stakeholders. Patients, hospitals and insurance companies "Hide
by David Curry, All Arundine Source: Richard Ivey School of Business Foundation 14 pages. Publication Date: March 1, 2006. Prod. #: 905M53-PDF-ENG
Related Case Solutions & Analyses:
Amar Chitra Katha: Changing the Brand with Changing Times
Pure Organic Food and Juice Bar
The University of Texas: Conference Realignment for College Athletics
HootSuite: Monetizing the Social Media Dashboard
Horseshoe Resort
Maple Leaf Simply Fresh (B)
Foreign Exchange Market and the Canadian Dollar: Some History and Background
eHarvest.com
COM DEV Xian: ISO 9000 Registration
HCM Beverage Co.
